全文获取类型
收费全文 | 2509539篇 |
免费 | 186070篇 |
国内免费 | 4004篇 |
专业分类
耳鼻咽喉 | 34020篇 |
儿科学 | 80415篇 |
妇产科学 | 66083篇 |
基础医学 | 368162篇 |
口腔科学 | 67178篇 |
临床医学 | 227964篇 |
内科学 | 488585篇 |
皮肤病学 | 54330篇 |
神经病学 | 202443篇 |
特种医学 | 95668篇 |
外国民族医学 | 501篇 |
外科学 | 380244篇 |
综合类 | 49240篇 |
现状与发展 | 13篇 |
一般理论 | 995篇 |
预防医学 | 194295篇 |
眼科学 | 58388篇 |
药学 | 186466篇 |
10篇 | |
中国医学 | 4766篇 |
肿瘤学 | 139847篇 |
出版年
2021年 | 22018篇 |
2019年 | 23149篇 |
2018年 | 31515篇 |
2017年 | 23585篇 |
2016年 | 26390篇 |
2015年 | 29810篇 |
2014年 | 42159篇 |
2013年 | 62401篇 |
2012年 | 87342篇 |
2011年 | 92605篇 |
2010年 | 54561篇 |
2009年 | 51612篇 |
2008年 | 86407篇 |
2007年 | 91892篇 |
2006年 | 92407篇 |
2005年 | 89809篇 |
2004年 | 85736篇 |
2003年 | 82103篇 |
2002年 | 79315篇 |
2001年 | 110211篇 |
2000年 | 112552篇 |
1999年 | 95044篇 |
1998年 | 29064篇 |
1997年 | 25194篇 |
1996年 | 23508篇 |
1995年 | 23853篇 |
1994年 | 21918篇 |
1993年 | 20718篇 |
1992年 | 72590篇 |
1991年 | 70769篇 |
1990年 | 68947篇 |
1989年 | 66173篇 |
1988年 | 60745篇 |
1987年 | 59526篇 |
1986年 | 55658篇 |
1985年 | 53508篇 |
1984年 | 39892篇 |
1983年 | 33909篇 |
1982年 | 20544篇 |
1979年 | 36138篇 |
1978年 | 25971篇 |
1977年 | 21468篇 |
1976年 | 20571篇 |
1975年 | 21993篇 |
1974年 | 26332篇 |
1973年 | 24969篇 |
1972年 | 23318篇 |
1971年 | 22140篇 |
1970年 | 20308篇 |
1969年 | 19340篇 |
排序方式: 共有10000条查询结果,搜索用时 234 毫秒
61.
Madan M. Rehani Emily R. Melick Raza M. Alvi Ruhani Doda Khera Salma Batool-Anwar Tomas G. Neilan Michael Bettmann 《European radiology》2020,30(4):1839-1846
To determine percent of patients without malignancy and ≤ 40 years of age with high cumulative radiation doses through recurrent CT exams and assess imaging appropriateness. From the cohort of patients who received cumulative effective dose (CED) of ≥ 100 mSv over a 5-year period, a sub-set was identified with non-malignant disease. The top 50 clinical indications leading to multiple CTs were determined. Clinical decision support (CDS) system scores were analyzed using a widely adopted standard of 1–3 (red) as “not usually appropriate,” 4–6 (yellow) “may or may not be appropriate,” and 7–9 (green) “usually appropriate.” Clinicians reviewed patient records to assess compliance with appropriate use criteria (AUC). 9.6% of patients in our series were with non-malignant conditions and 1.4% with age ≤ 40 years. CDS scores (rounded) were 2% red, 38% yellow, 27% green, and 33% unscored CTs. Clinical society guidelines for CT exams, wherever available, were followed in 87.5 to 100% of cases. AUCs were not available for several clinical indications as also referral guidelines for serial CT imaging. More than half of CT exams were unrelated to follow-up of a primary chronic disease. We are faced with a situation wherein patients in age ≤ 40 years require or are thought to require many CT exams over the course of a few years but the radiation risk creates concern. There is a fair number of conditions for which AUC are not available. Suggested solutions include development of CT scanners with lesser radiation dose and further development of appropriateness criteria. 相似文献
62.
Castro-Kemp Susana Palikara Olympia Gaona Carolina Eirinaki Vasiliki Furlong Michael J. 《School mental health》2020,12(2):284-295
School Mental Health - A dual approach to mental health in schools has been widely defended, where the assessment of psychological distress and the examination of strengths/well-being are two... 相似文献
63.
64.
Kenny P. Pang FRCSEd FRCSI Claudio Vicini MD Filippo Montevecchi MD Ottavio Piccin MD MSc Sudipta Chandra MBBS MS Hyung C. Yang MD PhD Vikas Agrawal MS DLO Joseph C. K. Chung FRCS Yiong H. Chan BSc PhD Scott B. Pang Kathleen A. Pang Edward B. Pang Brian Rotenberg MD MPH FRCSC 《The Laryngoscope》2020,130(9):2281-2284
65.
Michael Staehler Peter J. Goebell Lothar Müller Till-Oliver Emde Natalie Wetzel Lisa Kruggel Martina Jänicke Norbert Marschner the RCC-Registry Group 《International journal of cancer. Journal international du cancer》2020,146(5):1307-1315
Non-clear cell renal cell carcinoma is a very rare malignancy that includes several histological subtypes. Each subtype may need to be addressed separately regarding prognosis and treatment; however, no Phase III clinical trial data exist. Thus, treatment recommendations for patients with non-clear cell metastatic RCC (mRCC) remain unclear. We present first prospective data on choice of first- and second-line treatment in routine practice and outcome of patients with papillary mRCC. From the prospective German clinical cohort study (RCC-Registry), 99 patients with papillary mRCC treated with systemic first-line therapy between December 2007 and May 2017 were included. Prospectively enrolled patients who had started first-line treatment until May 15, 2016, were included into the outcome analyses (n = 82). Treatment was similar to therapies used for clear cell mRCC and consisted of tyrosine kinase inhibitors, mechanistic target of rapamycin inhibitors and recently checkpoint inhibitors. Median progression-free survival from start of first-line treatment was 5.4 months (95% confidence interval [CI], 4.1–9.2) and median overall survival was 12.0 months (95% CI, 8.1–20.0). At data cutoff, 73% of the patients died, 6% were still observed, 12% were lost to follow-up, and 9% were alive at the end of the individual 3-year observation period. Despite the lack of prospective Phase III evidence in patients with papillary mRCC, our real-world data reveal effectiveness of systemic clear cell mRCC therapy in papillary mRCC. The prognosis seems to be inferior for papillary compared to clear cell mRCC. Further studies are needed to identify drivers of effectiveness of systemic therapy for papillary mRCC. 相似文献
66.
Novozhilov A. V. Mindukshev I. V. Korf E. A. Krivchenko A. I. Goncharov N. V. 《Bulletin of experimental biology and medicine》2020,168(4):444-448
Bulletin of Experimental Biology and Medicine - Ammonium, an end-product of catabolism, in low doses can promote adaptation of metabolic pathways in erythrocytes under conditions of extreme... 相似文献
67.
68.
Anne E. Kazak Fang Fang Chen Wei‐Ting Hwang Martha A. Askins Gabriela Vega E. Anders Kolb Anne Reilly Lamia P. Barakat 《Pediatric blood & cancer》2020,67(2)
Purpose: Family psychosocial risk in pediatric oncology can be assessed using the Psychosocial Assessment Tool (PAT), a brief parent report screener based on the Pediatric Psychosocial Preventative Health Model (PPPHM; universal, targeted, and clinical). However, little is known about risk over the course of treatment and its association with medical and psychosocial healthcare utilization. Methods: Primary caregivers of children with cancer participated in this prospective multisite investigation, completing the PAT at diagnosis (T1; n = 396) and 6 months later (T2; n = 304). Healthcare utilization data were extracted from electronic health records. Results: The distribution of PPPHM risk levels at T1 and T2 was highly consistent for the samples. Two‐thirds of families remained at the same level of risk, 18% decreased and 16% increased risk level. Risk was not related to sociodemographic or treatment variables. The PAT risk score correlated with psychosocial contacts over the 6‐month period. Conclusions: Although the majority of families reported universal (low) risk on the PAT and were stable in their risk level over 6 months, reassessing risk is helpful in identifying those families who report higher level of risk during treatment than at diagnosis. PAT scores were related to psychosocial services that are provided to most but not all families and could be tailored more specifically to match risk and delivery of evidence‐based care. 相似文献
69.
70.